Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hirohata, Atsushi
EMPA-AHF, NCT05392764: Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure	Recruiting	3	524	Japan	Empagliflozin 10 MG, Placebo	Juntendo University, Boehringer Ingelheim	Acute Heart Failure	03/25	12/27
Hirohata
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Active, not recruiting	3	9541	Europe, Canada, Japan, US, RoW	Obicetrapib, Placebo	NewAmsterdam Pharma, Monash University	Atherosclerotic Cardiovascular Disease	11/26	11/26
Narchemashvil
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Active, not recruiting	3	9541	Europe, Canada, Japan, US, RoW	Obicetrapib, Placebo	NewAmsterdam Pharma, Monash University	Atherosclerotic Cardiovascular Disease	11/26	11/26